Hims & Hers down as judge denies motion over end to Lilly’s Zepbound shortage
Hims & Hers (HIMS) stock falls 8% as court denies injunction on FDA ruling for Eli Lilly's (LLY) Zepbound shortage. Read more here.
U.S. attorneys general forum urges FDA to act against counterfeit weight loss drugs
U.S. attorneys general urge the FDA to combat counterfeit versions of weight loss drugs developed by Eli Lilly (LLY) and Novo Nordisk (NVO). Read more here.
Eli Lilly takes aim at telehealth rivals in ‘Healthy Skepticism’ Oscars ad
Eli Lilly is airing an ad during the Academy Awards urging customers to adopt a health skepticism when marketed drug brands that are not FDA-approved.
US FDA says shortage of Novo's weight-loss drug resolved
The resolution comes two months after the health regulator said there was no longer a shortage of Eli Lilly's weight-loss and diabetes drugs. All doses of Novo's diabetes treatment Ozempic and weight-loss drug Wegovy were listed as available on the FDA's website in October,
WISH-TV13d
FDA declares end to Ozempic and Wegovy shortage
Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration said on Friday. The update about the popular semaglutide injections from drug manufacturer Novo Nordisk follows just two months after the FDA said that shortages of tirzepatide injections Zepbound and Mounjaro from competitor Eli Lilly had also ended.
US judge ruling for FDA bars copies of Lilly weight loss drug
A U.S. federal judge has denied an injunction that would have allowed compounding pharmacies to keep making copies of Eli Lilly's popular weight-loss drug Zepbound in the U.S. The decision was filed late on Wednesday in response to an October lawsuit from a compounding industry group against the U.
Hims & Hers down as judge denies motion over end to Lilly’s Zepbound shortage
Hims & Hers (NYSE:HIMS) fell ~8% in the premarket Thursday after a federal judge denied a motion filed by a compounding trade group over the FDA’s decision to declare that Eli Lilly’s (NYSE:LLY) weight loss drug Zepbound is no longer in shortage.
Telehealth firms Teladoc, LifeMD tie up with Eli Lilly's pharmacy partner to offer Zepbound
Telehealth firms Teladoc Health and LifeMD said on Thursday they have signed an agreement with Eli Lilly's direct-to-consumer website LillyDirect pharmacy partner, Gifthealth, to offer patients the weight-loss drug,
Fierce Pharma8h
In FDA obesity drug battle with compounders, Texas court allows Novo Nordisk to weigh in
As a federal court in Texas hears a case pitting the FDA versus compounders who want to continue to manufacture cheaper knockoff versions of popular weight loss drugs, Novo Nordisk will not have to | A federal district court in Texas will allow Novo Nordisk to intervene in a lawsuit pitting compounders against the FDA.
Court denying compounders’ motion positive for Eli Lilly, says Morgan Stanley
Morgan Stanley noted that two compounding groups – the Outsourcing Facilities Association and North American Custom Laboratories – filed a
Modern Healthcare5h
Teladoc, LifeMD partner with Eli Lilly on GLP-1s
The partnership comes as telehealth companies grapple with restrictions on the sale of some compounded GLP-1s.
Fierce Pharma1d
Lilly’s 1st DTC Ebglyss campaign highlights eczema’s effects on a range of skin tones and age groups
After scoring a long-awaited FDA approval last fall, Eli Lilly has launched a consumer-facing campaign to get the word out about its atopic dermatitis treatment Ebglyss.